FDG-PET imaging in the management of non-small-cell lung cancer

被引:9
|
作者
Salminen, E
Mac Manus, M
机构
[1] Turku Univ Hosp, Dept Radiotherapy & Oncol, FIN-20520 Turku, Finland
[2] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
关键词
FDG-PET; non-small-cell lung cancer; outcome; staging; treatment;
D O I
10.1093/annonc/mdf106
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung cancer is currently the leading cause of cancer-related death in both men and women in most Western countries. Tumour stage is the strongest prognostic factor and the most important parameter guiding treatment decision making. Metabolic positron emission tomography imaging with fluorodeoxyglucose (FDG-PET) has consistently proved superior to conventional imaging for staging of non-small-cell lung cancer and provides information of greater prognostic significance than can be obtained using conventional approaches. FDG-PET has been approved in the USA. Germany and the UK as a basic and invaluable tool in the management of lung cancer.
引用
收藏
页码:357 / 360
页数:4
相关论文
共 50 条
  • [1] Impact of FDG-labelled positron emission tomography imaging on the management of non-small-cell lung cancer
    Salminen, E
    Mac Manus, M
    ANNALS OF MEDICINE, 2001, 33 (06) : 404 - 409
  • [2] Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer
    Lee, Ho-Young
    Chung, June-Key
    Jeong, Jae Min
    Lee, Dong Soo
    Kim, Dong Gyu
    Jung, Hee Won
    Lee, Myung Chul
    ANNALS OF NUCLEAR MEDICINE, 2008, 22 (04) : 281 - 286
  • [3] Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer
    Bradley, J
    Thorstad, WL
    Mutic, S
    Miller, TR
    Dehdashti, F
    Siegel, BA
    Bosch, W
    Bertrand, RJ
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (01): : 78 - 86
  • [4] Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer
    Ho-Young Lee
    June-Key Chung
    Jae Min Jeong
    Dong Soo Lee
    Dong Gyu Kim
    Hee Won Jung
    Myung Chul Lee
    Annals of Nuclear Medicine, 2008, 22
  • [5] FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer
    Mitsunori Higuchi
    Yuki Owada
    Takuya Inoue
    Yuzuru Watanabe
    Takumi Yamaura
    Mitsuro Fukuhara
    Takeo Hasegawa
    Hiroyuki Suzuki
    World Journal of Surgical Oncology, 14
  • [6] Value of FDG-PET in the management of non-small cell lung cancer
    Stroobants, S
    Verschakelen, J
    Vansteenkiste, J
    EUROPEAN JOURNAL OF RADIOLOGY, 2003, 45 (01) : 49 - 59
  • [7] FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer
    Higuchi, Mitsunori
    Owada, Yuki
    Inoue, Takuya
    Watanabe, Yuzuru
    Yamaura, Takumi
    Fukuhara, Mitsuro
    Hasegawa, Takeo
    Suzuki, Hiroyuki
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14
  • [8] Staging of non-small-cell lung cancer and application of FDG-PET - A cost modeling approach
    Verboom, P
    Herder, GJM
    Hoekstra, OS
    Smit, EF
    van den Bergh, JHAM
    van Velthoven, PCM
    Grijseels, EWM
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2002, 18 (03) : 576 - 585
  • [9] Diagnostic and prognostic values of FDG-PET in patients with non-small cell lung cancer
    Abe, Koichiro
    Baba, Shingo
    Kaneko, Koichiro
    Isoda, Takuro
    Yabuuchi, Hidetake
    Sasaki, Masayuki
    Sakai, Shuji
    Yoshino, Ichiro
    Honda, Hiroshi
    CLINICAL IMAGING, 2009, 33 (02) : 90 - 95
  • [10] Small cell lung cancer: role of FDG-PET and PET/CT
    Baum, R. R.
    Prasad, V.
    ONKOLOGE, 2008, 14 (08): : 774 - +